294 related articles for article (PubMed ID: 26115203)
21. Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia.
Chen C; Han CH; Sweeney M; Cowles VE
J Pharm Sci; 2013 Apr; 102(4):1155-64. PubMed ID: 23381946
[TBL] [Abstract][Full Text] [Related]
22. The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study.
North JM; Hong KS; Rauck RL
Pain Pract; 2016 Jul; 16(6):720-9. PubMed ID: 26059271
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials.
Fan H; Yu W; Zhang Q; Cao H; Li J; Wang J; Shao Y; Hu X
J Clin Pharm Ther; 2014 Aug; 39(4):334-42. PubMed ID: 24806220
[TBL] [Abstract][Full Text] [Related]
24. Relationships Among Adverse Events, Disease Characteristics, and Demographics in Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin.
Shaparin N; Slattum PW; Bucior I; Nalamachu S
Clin J Pain; 2015 Nov; 31(11):983-91. PubMed ID: 25811794
[TBL] [Abstract][Full Text] [Related]
25. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings.
Gore M; Sadosky A; Tai KS; Stacey B
Clin Ther; 2007 Aug; 29(8):1655-70. PubMed ID: 17919547
[TBL] [Abstract][Full Text] [Related]
26. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study.
Rice ASC; Maton S;
Pain; 2001 Nov; 94(2):215-224. PubMed ID: 11690735
[TBL] [Abstract][Full Text] [Related]
27. Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN).
Markley HG; Dunteman ED; Kareht S; Sweeney M
Clin J Pain; 2015 Jan; 31(1):58-65. PubMed ID: 25076463
[TBL] [Abstract][Full Text] [Related]
28. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain.
White WT; Patel N; Drass M; Nalamachu S
Pain Med; 2003 Dec; 4(4):321-30. PubMed ID: 14750908
[TBL] [Abstract][Full Text] [Related]
29. Severe postherpetic neuralgia and other neuropathic pain syndromes alleviated by topical gabapentin.
Hiom S; Patel GK; Newcombe RG; Khot S; Martin C
Br J Dermatol; 2015 Jul; 173(1):300-2. PubMed ID: 25524254
[No Abstract] [Full Text] [Related]
30. Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy.
Ifuku M; Iseki M; Hidaka I; Morita Y; Komatus S; Inada E
Pain Med; 2011 Jul; 12(7):1112-6. PubMed ID: 21692969
[TBL] [Abstract][Full Text] [Related]
31. N-of-1 randomized trials to assess the efficacy of gabapentin for chronic neuropathic pain.
Yelland MJ; Poulos CJ; Pillans PI; Bashford GM; Nikles CJ; Sturtevant JM; Vine N; Del Mar CB; Schluter PJ; Tan M; Chan J; Mackenzie F; Brown R
Pain Med; 2009; 10(4):754-61. PubMed ID: 19453961
[TBL] [Abstract][Full Text] [Related]
32. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin.
Vinik A; Emir B; Cheung R; Whalen E
Clin Ther; 2013 May; 35(5):612-23. PubMed ID: 23541708
[TBL] [Abstract][Full Text] [Related]
33. Gabapentin for once-daily treatment of post-herpetic neuralgia: a review.
Beal B; Moeller-Bertram T; Schilling JM; Wallace MS
Clin Interv Aging; 2012; 7():249-55. PubMed ID: 22866002
[TBL] [Abstract][Full Text] [Related]
34. The intestinal absorption mechanism of gabapentin makes it appropriate for gastroretentive delivery.
Chen C; Cowles VE; Sweeney M
Curr Clin Pharmacol; 2013 Feb; 8(1):67-72. PubMed ID: 22946876
[TBL] [Abstract][Full Text] [Related]
35. A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders.
Harden RN; Freeman R; Rainka M; Zhang L; Bell C; Berges A; Chen C; Graff O; Harding K; Hunter S; Kavanagh S; Schwartzbach C; Warren S; McClung C
Pain Med; 2013 Dec; 14(12):1918-32. PubMed ID: 24102928
[TBL] [Abstract][Full Text] [Related]
36. Impact of Data Imputation Methodology on Pain Assessment over 24 Hours in a Randomized, Placebo-Controlled Study of Gabapentin Enacarbil in Patients with Neuropathic Pain Associated with Postherpetic Neuralgia.
Calkins AM; Gudin J; Gidal B; Jaros MJ; Kim R; Shang G
Pain Med; 2016 Apr; 17(4):728-36. PubMed ID: 26814307
[TBL] [Abstract][Full Text] [Related]
37. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
Kirson NY; Ivanova JI; Birnbaum HG; Wei R; Kantor E; Puenpatom RA; Ben-Joseph RH; Summers KH
J Med Econ; 2010; 13(3):482-91. PubMed ID: 20684669
[TBL] [Abstract][Full Text] [Related]
38. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin.
Zin CS; Nissen LM; O'Callaghan JP; Duffull SB; Smith MT; Moore BJ
J Pain; 2010 May; 11(5):462-71. PubMed ID: 19962354
[TBL] [Abstract][Full Text] [Related]
39. Once-daily gabapentin (Gralise) for postherpetic neuralgia.
Medical Letter
Med Lett Drugs Ther; 2011 Nov; 53(1378):94. PubMed ID: 22113123
[No Abstract] [Full Text] [Related]
40. Brief pain inventory--facial minimum clinically important difference.
Sandhu SK; Halpern CH; Vakhshori V; Mirsaeedi-Farahani K; Farrar JT; Lee JY
J Neurosurg; 2015 Jan; 122(1):180-90. PubMed ID: 25361481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
